Sterling/Yamanouchi joint venture
Executive Summary
Sterling's joint venture with the Japanese firm, to be known as Sterling-Yamanouchi, will commercialize Sterling's ethical drugs in Japan. Under the agreement, Yamanouchi will be the exclusive distributor of the joint venture's products in Japan. The venture, which is subject to Japanese regulatory approval, will be co-owned by Sterling (51%) and Yamanouchi (49%). Sterling said its existing licenses in Japan will remain intact and its OTC and consumer products will continue to be marketed through Sterling-Winthrop.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.